A desire for sustainable growth is pushing gene therapy biotechs to be strategic about manufacturing and pipelines.

The EC has approved an extended use of Johnson & Johnson's Tecvayli, along with daratumumab, to treat adult patients with relapsed or refractory multiple myeloma (r/r MM).

WellSpan Health and Johns Hopkins Medicine have renewed their oncology collaboration to widen access to advanced care throughout central Pennsylvania, US.

Sandoz and Henlius will collaborate on up to 10 biosimilars amid opportunity to capitalise on global biosimilar loss-of-exclusivities.

The UK’s National Institute for Health and Care Excellence (NICE) has issued a positive recommendation for Eli Lilly’s Onswik (efsitora alfa) in a move that opens the insulin jab up for national ...

Tanabe’s dersimelagon is already under FDA review having achieved positive Phase III results earlier this year.

Alfasigma is to buy Nordic Group, which aims to strengthen its speciality care business and expand its reach in Europe, Canada, and Japan.

Kynexis will now prepare for registrational studies on lead asset, KYN-5356 in cognitive impairment associated with schizophrenia (CIAS).

Faeth Therapeutics has received fast track designation from the FDA for the PIKTOR with paclitaxel combination to treat advanced or recurrent endometrial cancer.

Ultragenyx Pharmaceutical has received accelerated approval from the FDA for its gene therapy, Genglycos, to treat GSDIa.

Andelyn Biosciences is set to develop and manufacture a gene therapy known as AAV9-GM2, for Queen’s University to treat GM2 gangliosidoses, including Tay-Sachs and Sandhoff diseases.

The FDA has granted accelerated approval to BMS' Zenbexus, along with daratumumab and hyaluronidase-fihj and dexamethasone (ZDd), to treat adult multiple myeloma.